Item 5. Other Information
Item 5. Other Information
During the three months ended June 30, 2026, no director or officer of the Company adopted or terminated any “Rule 10b5-1 trading arrangement” or any “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Item 408 of Regulation S-K.
5
Item 6. Exhibits
3.1 Certificate of Amendment to the Certificate of Incorporation, effective July 23, 2026.
10.1 Confidential Settlement Agreement and Mutual Release, dated April 24, 2026 (incorporated by reference to the Company’s Current Report on Form 8-K filed May 4, 2026).
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.3 Certification of Co-Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 Certification of Principal Executive Officers and Principal Financial Officer pursuant to 18 U.S.C. Section 1350.
101 Inline XBRL documents.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
6
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
APIMEDS PHARMACEUTICALS US, INC.
By: / s / Dr. Vin Menon
Dr. Vin Menon, Co-Chief Executive Officer
(Principal Executive Officer)
By: / s / Sungjoon Chae
Sungjoon Chae, Co-Chief Executive Officer
(Principal Executive Officer)
By: / s / Erick Frimm
Erick Frim, Chief Financial Officer
(Principal Financial Officer)
Date: August 14, 2026
7
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.